SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Meda AB denies any stake sale talks with Sun Pharmaceutical

06 Jun 2013 Evaluate

Swedish drug firm Meda AB has clarified that it is not in any discussions with Sun Pharmaceutical Industries for a $5 billion stake sale. Earlier, it was reported that Sun Pharmaceutical Industries, country’s third largest drug maker by sales, was in talks to acquire Meda AB in a deal potentially worth of about $5 billion. Further, it was also reported that letter of intent for acquisition was signed and due diligence process was soon to start and be completed within 6 months.

Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×